S02.2 · Healthcare & Life Sciences
A $430-500B volume manufacturing base squeezed between PBM rebates and India/China-concentrated production.
Generic and specialty pharma manufacturing is the volume backbone of the global drugs market — an estimated $430-500B in 2025, the range reflecting differing generics/specialty scope definitions across Grand View Research and Precedence Research. Forward growth of 6-8% on patent expiries and government cost containment sounds comfortable. It is not. Price is set externally, PBM rebate contracts squeeze from the demand side, India/China-concentrated production squeezes from the supply side, and the segment's central structural feature is the split between where revenue is booked and where product is made.
Growth ran 6-7% historically, 6-8% projected forward. Revenue concentrates in the US, EU and India; production — API and finished dose alike — sits heavily in India and China. That gap is now a recurring supply-chain and geopolitical exposure across the sector, not a one-off shock. Competitively the market is fragmented: the top 10 generics players, including Teva, Viatris, Sandoz and Sun Pharma, hold well under 30% combined, above a deep long tail of regional and national manufacturers.
The chain runs from API producers and CDMOs upstream to wholesalers, PBMs and retail/hospital pharmacy downstream. Economics are thin and commoditized — 20-40% gross margins, volume-driven, with government formularies and PBM rebate contracts grinding standard-generic prices down year after year. The capital is going where the margin is: specialty generics — biosimilars and complex injectables — carry materially higher margins, and that is where operators are directing it.
Agentic AI is automating batch-record review, quality and compliance documentation, and demand forecasting — squarely the QA and regulatory-affairs headcount line. In a business where formularies and rebate contracts set price, QA/regulatory cost is one of the few levers management actually controls, which makes this compression worth more here than in most segments. It also narrows the scale-manufacturing moat: AI-driven process optimization no longer requires the scale to justify a dedicated data-science team, so the cost gap between large and mid-sized manufacturers is closing.
The strategic moves split by what they do to revenue. Biosimilar entry adds new, higher-margin specialty revenue — genuine growth, not defense of the existing base. API backward integration defends: it buys supply security after COVID-era and tariff-driven shocks exposed how concentrated finished-dose production had become. Consumer health OTC conversion is a third adjacency, extending branded-generic products into a cash-pay retail channel. Quality/compliance automation is already underway; AI-optimized manufacturing scheduling at scale is a 2-5 year horizon.